Kageyama Aiko, Fujino Tomomi, Taki Yuko, Kato Yoshihisa, Nozawa Yoshihisa, Ito Yoshihiko, Yamada Shizuo
Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Neurosci Lett. 2008 May 2;436(1):81-4. doi: 10.1016/j.neulet.2008.02.065. Epub 2008 Mar 5.
We characterized muscarnic and purinergic receptors and urodynamic parameters in the bladder of cyclophosphamide (CYP)-treated rats to clarify the mechanisms involved in the pathophysiology of interstitial cystitis (IC). In the cystometry of CYP-treated rats compared with control rats, the micturition interval and micturition volume were significantly (55% and 77%, respectively) decreased and the frequency of micturition and basal pressure were significantly (3 and 2.3 times, respectively) increased. These changes in urodynamic parameters may characterize the detrusor overactivity occurring in CYP-treated rats. The maximal number of binding sites (B(max)) for specific binding of [N-methyl-(3)H]scopolamine methyl chloride ([(3)H]NMS) and alphabeta-methylene ATP [2,8-(3)H]tetrasodium salt ([(3)H]alphabeta-MeATP) was significantly (43% and 31%, respectively) decreased in the bladder of CYP-treated rats compared with control rats. On the other hand, the apparent dissociation constant (K(d)) for neither radioligand was significantly altered by the CYP treatment. K(i) value for the inhibition of bladder [(3)H]NMS binding by antimuscarinic agents (oxybutynin, tolterodine, darifenacin, and AF-DX 116) did not differ significantly between control and CYP-treated rats. The inhibition constant (K(i)) for the inhibition of bladder [(3)H]alphabeta-MeATP binding by purinergic antagonists (A-317491, PPADS) was significantly higher in CYP-treated rats than control rats. In conclusion, CYP treatment has been shown to cause down-regulation of pharmacologically relevant (muscarinic and purinergic) receptors in the bladder of rats. Thus, the present study offers further pharmacological evidence that both muscarinic and purinergic mechanisms contribute significantly to the urinary dysfunction due to IC.
我们对环磷酰胺(CYP)处理的大鼠膀胱中的毒蕈碱能和嘌呤能受体以及尿动力学参数进行了表征,以阐明间质性膀胱炎(IC)病理生理学所涉及的机制。与对照大鼠相比,在CYP处理大鼠的膀胱测压中,排尿间隔和排尿量显著降低(分别降低55%和77%),排尿频率和基础压力显著增加(分别增加3倍和2.3倍)。尿动力学参数的这些变化可能是CYP处理大鼠中发生的逼尿肌过度活动的特征。与对照大鼠相比,CYP处理大鼠膀胱中[甲基 - (3)H]东莨菪碱甲基氯([(3)H]NMS)和αβ - 亚甲基ATP [2,8 - (3)H]四钠盐([(3)H]αβ - MeATP)特异性结合的最大结合位点数量(B(max))显著降低(分别降低43%和31%)。另一方面,CYP处理并未使两种放射性配体的表观解离常数(K(d))发生显著改变。抗毒蕈碱药物(奥昔布宁、托特罗定、达非那新和AF - DX 116)对膀胱[(3)H]NMS结合的抑制K(i)值在对照大鼠和CYP处理大鼠之间无显著差异。嘌呤能拮抗剂(A - 317491、PPADS)对膀胱[(3)H]αβ - MeATP结合的抑制常数(K(i))在CYP处理大鼠中显著高于对照大鼠。总之,已证明CYP处理会导致大鼠膀胱中与药理学相关(毒蕈碱能和嘌呤能)受体的下调。因此,本研究提供了进一步的药理学证据,表明毒蕈碱能和嘌呤能机制均对IC所致的排尿功能障碍有显著贡献。